Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying the side effects of gemcitabine and to see how well it works
in treating patients with recurrent or persistent endometrial cancer. Drugs used in
chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing.